Health‐care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis

Chen, Yaozhu J.; Tang, Wenxi; Ionescu‐Ittu, Raluca; Ayyagari, Rajeev; Wu, Eric Q.; Huh, Susanna Y.; Parkman, Henry P.

doi:10.1111/nmo.14366

Cited by 13 publications

(16 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous data for diabetes gastroparesis reported more frequent hospitalizations, and more hospital days, office visits, and emergency department visits. 17 Gastroparesis patients were also more likely to have more sick leave for 2 years after the first diagnosis, as previously reported by Jehangir et al 18 Those findings may contribute to the higher cost for gastroparesis (with ratio of 1.96 compared to the controls, similar to approximately twice the costs in the US cohort 21 ), which increased according to the degree of gastroparesis treatment.…”

Section: Discussionsupporting

confidence: 67%

“…5 In a recently published analysis of a large commercial claims database, both diabetic and idiopathic gastroparesis were more likely to have a greater healthcare resource utilization compared to matched controls. 21 The aim of this study was to estimate the epidemiology and the short-term burden of gastroparesis in a large population-based cohort using data from a state-mandated health provider in Israel.…”

Section: Introductionmentioning

confidence: 99%

“…The number of gastroparesis‐related hospitalizations has been increasing in the United States (158% increase between 1995 and 2004) with a significant economic impact (48 million dollars of hospital charges) 5 . In a recently published analysis of a large commercial claims database, both diabetic and idiopathic gastroparesis were more likely to have a greater healthcare resource utilization compared to matched controls 21 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The epidemiology and burden of gastroparesis: Real‐world data from a large healthcare provider in Israel

Yekutiel

Chodick

Knop

et al. 2023

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background: Gastroparesis is a gastrointestinal motility dysfunction characterized by delayed gastric emptying in the absence of gastric mechanical obstruction. Data on the epidemiology of gastroparesis are sparse even though the condition substantially impairs patients' quality of life. The aim of this study was to describe the epidemiology and estimate the short-term healthcare resource use burden of gastroparesis in a large population. Methods:This cross-sectional study utilized computerized data from Maccabi Healthcare Services, a 2.5-million member state-mandated health organization in Israel. Data were collected between 2003 and 2018 to assess the prevalence of gastroparesis. Definite gastroparesis was defined by gastroparesis diagnosis and gastric emptying test. Probable gastroparesis was defined by gastroparesis diagnosis only.To compare the healthcare resource utilization (HCRU), data were also collected on controls that were individually matched (1:2) for age, sex, and comorbidities. Key Results: A total of 522 patients with gastroparesis were identified (21.1 per 100,000 WHO age-standardized), including 204 with definite gastroparesis (8.6 per 100,000 WHO). Male to female ratio was 1:2 and mean ± SD age of 54.7 ± 17.1 years.Diabetes accounted for 25.9% of gastroparesis cases and the rest were idiopathic.Gastroparesis patients were more likely to have cardiovascular diseases (10% vs. 6.9% for controls, p = 0.034) and lower prevalence of obesity (17% vs. 24.4%, p < 0.001).HCRU within the 2 years after index date were higher with more hospitalizations than controls (26.4% vs. 15.4%, p < 0.001), and more emergency room visits (31.6% vs. 24.1%, p = 0.002). Conclusions & Inferences:Gastroparesis is uncommon or under-documented in community care settings. Gastroparesis in general is associated with cardiovascular morbidities, lower BMI, and elevated utilization of healthcare services.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The epidemiology and burden of gastroparesis: Real‐world data from a large healthcare provider in Israel

Yekutiel

Chodick

Knop

et al. 2023

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…Patients often need long-term, continued care comprising non-pharmacological and pharmacological interventions [2]. In addition, costs related to hospitalizations are relevant and, in the US, healthcare costs related to gastroparesis have increased significantly since 2017 [10,12].…”

Section: Introductionmentioning

confidence: 99%

Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis. Methods We searched EMBASE and MEDLINE up to March 25, 2021, for relevant clinical trials and observational studies. We conducted a proportional meta-analysis to estimate the pooled occurrence of AEs (%), with 95% confidence interval (CI), from arm-level data across studies and the comparative occurrence of AEs from placebo-controlled clinical trials (odds ratio [OR] with 95% CI). Results We identified 28 studies assessing AEs experienced by patients treated for gastroparesis with domperidone and metoclopramide; 22 studies contributed data to the meta-analyses. Cardiovascular, neurological, and endocrine AEs were commonly observed, with point incidences varying from 1 to > 50%. Clinically important AEs, such as QTc prolongation, occurred in 5% of patients treated with domperidone (95% CI: 3.32-8.62). Restlessness, an extrapyramidal AE, occurred in 15% of patients (95% CI: 7.48-26.61) treated with metoclopramide, with a 7-fold increase compared with patients receiving placebo (OR: 7.72; 95% CI: 1.27-47.05). Variation in terminology to describe extrapyramidal events precluded further pooled analyses. Additional meta-analyses were not feasible due to discrepancies in the assessment and reporting of the AEs. Conclusions The evidence confirms concerns of cardiovascular, extrapyramidal, and endocrine AEs in patients with gastroparesis treated with domperidone and metoclopramide. Imprecise AE reporting limits firm interpretation and conclusions. Registration PROSPERO international prospective register of systematic reviews (registration number: CRD42021248888).

show abstract

“…Despite their prevalence and cost to the healthcare system ( 1 – 3 ), most patients with gastroparesis and functional dyspepsia are “idiopathic” with a cause yet to be identified ( 4 ). Historically, gastroparesis has been considered a separate entity from functional dyspepsia, a disorder of chronic upper abdominal symptoms similarly characterized by early satiety and epigastric pain in the absence of the delayed gastric emptying study defining gastroparesis.…”

Section: Introductionmentioning

confidence: 99%

Pancreatitis and the Risk of Developing Gastric Neuromuscular Dysfunction

Pasricha

Staller

Kuo

2022

Clin Transl Gastroenterol

View full text Add to dashboard Cite

INTRODUCTION: Most gastroparesis and functional dyspepsia cases (collectively, gastric neuromuscular dysfunction [GND]) remain idiopathic. It is believed that some idiopathic cases of GND may be triggered by an inflammatory insult to the gastrointestinal tract. We theorized that the profound foregut inflammation induced by pancreatitis could result in increased risk of GND. METHODS: This was a case-control study of all patients undergoing gastric emptying scintigraphy between October 2017 and 2020 in an urban medical center with presumed GND. These were age-, sex-, and comparative health-matched to control patients with newly diagnosed microscopic colitis. Adjusted odds ratios (aORs) were calculated using conditional logistic regression. RESULTS: Among the 650 patients with GND, 359 had gastroparesis, and 9.2% had a history of acute pancreatitis (vs 3.1% of controls). Patients with GND demonstrated increased odds of having a history of acute pancreatitis (aOR 2.27, 95% confidence interval [CI] 1.33–4.03, P = 0.004) and recurrent pancreatitis (aOR 2.08, 95% CI 1.67–3.48, P = 0.002). Median time to GND diagnosis after first acute pancreatitis episode was 1,544 days (477.5, 3,832). Patients with a history of pancreatitis-associated GND had increased mortality vs controls (aOR 3.41, 95% CI 0.96–5.48). In addition, patients with pancreatitis-associated GND had more hospitalizations vs GND alone (13.8 vs 3.7, P < 0.0001) during the study period. DISCUSSION: This is the first study demonstrating an independent association between pancreatitis and the risk of GND, which occurred ∼4.2 years after the first episode of acute pancreatitis. Pancreatitis should therefore be regarded as a possible risk factor for developing GND with important consequences for healthcare utilization.

show abstract

Health‐care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis

Cited by 13 publications

References 40 publications

The epidemiology and burden of gastroparesis: Real‐world data from a large healthcare provider in Israel

The epidemiology and burden of gastroparesis: Real‐world data from a large healthcare provider in Israel

Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis

Pancreatitis and the Risk of Developing Gastric Neuromuscular Dysfunction

Contact Info

Product

Resources

About